

NOVEL PEPTIDE–CARRIER CONJUGATES FOR USE IN TREATMENT OF ALZHEIMER DISEASE (AD)

PROBLEM DESCRIPTION

AD is the most common cause of age-related dementia worldwide. The number of cases grows rapidly. The number of AD patients is expected to grow up to 75.6 million in 2030.

No effective therapy has been proposed so far. A β oligomers are strong neurotoxins and their presence correlates with the progression of pathological changes in patients with AD. Thus A β oligomers may be a promising target for the effective therapy.

STAGE OF DEVELOPMENT

DISCOVERY

VERIFIED IN ANIMAL MODEL

TOXICOLOGY DONE

PHASE I CT

PHASE II CT

INNOVATION OF THE SOLUTION

Nencki's first-in-class potential drug enables addressing the promising approach to AD therapy. It utilizes novel conjugates comprising of short synthetic peptides linked with a carrier molecule. These novel peptides inhibit the formation of neurotoxic A β oligomers as well as neutralize already formed oligomers.

THE MOST IMPORTANT ADVANTAGES

Novel approach enabling effective AD prevention and treatment.

No toxicity and immunogenicity in preliminary animal studies.

Low synthesis and formulation costs.

Increased biostability.

PROJECT CORE TEAM

[Krzysztof Nieznański](#)

[Hanna Nieznańska](#)

KEY PUBLICATION

Nieznanska H, et al. 2018. Biochim Biophys Acta Mol Basis Dis.

DOI: 10.1016/j.bbadis.2021.166209

Nieznanska H, et al. 2021. Biochim Biophys Acta Mol Basis Dis.

DOI: 10.1016/j.bbadis.2018.03.023

KEY WORDS



DRUG



NEUROLOGICAL DISEASES



NEW MECHANISM



BIOLOGICS

INTELLECTUAL PROPERTY STATUS

Patent granted in US10815292, EP3468577

Patent pending in IL 262902

Priority date 11 May 2016

CONTACT DETAILS

DOROTA GIEREJ-CZERKIES

phone +48 22 589 22 63 | e-mail: d.gierej-czerkies@nencki.edu.pl

www.nencki.edu.pl